Pharma BD Deal Intelligence
Amgen acquired Onyx Pharmaceuticals for $10.4B for cancer drug portfolio.
Kyprolis failed its Phase III Clarion trial, showing survival rates on par with generic Velcade rather than superiority — a major pipeline failure to the tune…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Amgen acquired Onyx Pharmaceuticals for $10.4B for cancer drug portfolio.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Amgen Inc. / Onyx Pharmaceuticals (this deal) | 2013 | $10.4B | 67 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| Amgen Inc. / Otezla (from Celgene/BMS) | 2019 | $13.4B | 68 |
← Browse all deals · How we score deals
More: 2013 deals · Amgen Inc. deals · Oncology deals